Laurus Labs informed on Wednesday that the company has invested Rs 80 crore in Immunoadoptive Cell Therapy Private Ltd (lmmunoACT). Reportedly, lmmunoACT is developing a CAR T-cell therapy to cure specific types of blood cancers.
As part of series-B funding, Laurus will receive an additional stake of 7.24% in lmmunoACT. After the completion of the said funding round, Laurus will hold a 33.86% stake in lmmunoACT on a fully diluted basis.
Earlier in November 2021, Laurus acquired a 26.62% stake in ImmunoACT. The said acquisition was for an aggregate consideration of about Rs 46 crore.
The fresh equity infusion will aid lmmunoACT to accelerate the scale-up of its lead candidate HCAR-19 by expanding its multi-location cGMP facilities and R&D of the new product pipeline.
This investment by Laurus will help lmmunoACT to prepare for manufacturing more treatments. Laurus Labs is looking to invest in revolutionary innovation and help its strategic partners and customers introduce these promising therapies to patients.
lmmunoACT is looking to expand its collaboration with institutions like Tata Memorial Hospital.
For feedback and suggestions, write to us at editorial@iifl.com
Related Tags
IIFL Customer Care Number
(Gold/NCD/NBFC/Insurance/NPS)
1860-267-3000 / 7039-050-000
IIFL Securities Support WhatsApp Number
+91 9892691696
www.indiainfoline.com is part of the IIFL Group, a leading financial services player and a diversified NBFC. The site provides comprehensive and real time information on Indian corporates, sectors, financial markets and economy. On the site we feature industry and political leaders, entrepreneurs, and trend setters. The research, personal finance and market tutorial sections are widely followed by students, academia, corporates and investors among others.
Stock Broker SEBI Regn. No: INZ000164132, PMS SEBI Regn. No: INP000002213,IA SEBI Regn. No: INA000000623, SEBI RA Regn. No: INH000000248
This Certificate Demonstrates That IIFL As An Organization Has Defined And Put In Place Best-Practice Information Security Processes.